Crizotinib (Xalkori), the first‐class ALK TKI showed superiority to platinum‐pemetrexed chemotherapy in ALK‐positive NSCLC. Crizotinib has shown >60% overall response rate in ALK‐positive NSCLC, improving PFS significantly as compared to second‐line chemotherapy. Ceritinib (Zykadia), a next‐generation ALK inhibitor, has shown durable response in NSCLC patients pretreated with another ALK TKI, and in ALK TKI naive patients. Alectinib (Alecensa) has shown systemic and central nervous system effectiveness in NSCLC Brigatinib (Alunbrig) Lorlatinib (Lorbrena). The gene discussed is ALK; the disease is non-small cell lung carcinoma.